The newly emerged SARS-Like coronavirus HCoV-EMC also has an “Achilles’ heel”: current effective inhibitor targeting a 3C-like protease  

作　　者：Zhilin Ren Liming Yan Ning Zhang Yu Guo Cheng Yang Zhiyong Lou Zihe Rao 

机构地区：[1]College of Pharmacy and State Key Laboratory of Medicinal Chemical Biology,Nankai University,Tianjin 300071,China [2]Structural Biology Laboratory and MOE Laboratory of Protein Science,School of Medicine and Life Science,Tsinghua University,Beijing 100084,China [3]National Laboratory of Macromolecules,Institute of Biophysics,Chinese Academy of Science,Beijing 100101,China [4]Emerging Infection Disease Program,High-throughput Molecular Drug Discovery Center,Tianjin Joint Academy of Biomedicine and Technology,Tianjin 300457,China

出　　处：《Protein & Cell》2013年第4期248-250,共3页蛋白质与细胞（英文版）

基　　金：supported by the National Basic Research Program(973 Program);National Natural Science Foundation of China.

摘　　要：From the global outbreak of SARS-CoV caused infection disease in 2003,coronaviruses(CoVs)are known to be a great threat to the human health.Recently,a new SARS-like coronavirus,human betacoronavirus 2c EMC/2012(HCoV-EMC),has been identified and the appearance of this new CoV raises concerns that a new spread of CoV may occurs in the future.By solving the crystal structure of HCoV-EMC main protease with a wide-spectrum anti-CoV inhibitor N3,we confi rmed that that N3 blocks the function of HCoV-EMC main protease through a similar mechanism to other CoVs.Together with the good pharmaceutical features,N3 is conceivable to be effective to HCoV-EMC and other CoVs appearing in the future.These fi ndings make it convincing that CoVs will not be a threat to human health.

关 键 词：EMC SARS Together 

分 类 号：R37[医药卫生—病原生物学]